biostudies-literatureUnknown6(3)Bolanos-Meade JNational Institute of Allergy and Infectious DiseasesU.S. Department of Health and Human ServicesNHLBI NIH HHSNational Heart, Lung, and Blood InstituteNational Cancer InstituteNCI NIH HHSHealth Resources and Services AdministrationThe Lancet. Haematologye132-e143https://www.ebi.ac.uk/biostudies/studies/S-EPMC6503965biostudies-literatureThree prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).PMC6503965P30 CA008748U24-CA76518UG1 HL069290UG1 HL069291HHSH234200637015CUG1 HL109137U24 HL138660UG1 HL069310U10 HL069294UG1 HL108945P01 CA049605U10 HL069291U24 CA076518UG1 HL069315UG1 HL069249Chen YBWu JJones RJBickett KMacMillan MLLogan BRMielcarek MKoreth JPidala JGeller NLJacobsohn DAWeisdorf DJBolanos-Meade JHorowitz MMPorter DLGiralt SAAbhyankar SNoel PFei MFraser RHoltan SGReshef REfebera YAHari PSobecks RPasquini MCPusic ISolomon SRDamon LEArai SAntin JHLiesveld JLAlousi AMAl-Kadhimi ZfalseThree prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203).2019-01-01T00:00:00Z2019 Mar2026-05-07T13:24:09.578Z2025-04-06T18:53:25.822ZS-EPMC65039653082404010.1016/s2352-3026(18)30221-710.1016/S2352-3026(18)30221-7